Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy
Despite significant advancements in the understanding of cancer and the development of countless novel therapeutic modalities, resistance and relapse remain persistent and pervasive issues across tumor types even in the setting of cutting-edge treatments. The situation is particularly dire for tumor...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2024
|
| Online Access: | https://hdl.handle.net/1721.1/156275 |